ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.15
-0.09 (-1.63%)
Sep 10, 2026, 9:53 AM EDT - Market open
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $33.66M in the quarter ending June 30, 2026, with 114.15% growth. This brings the company's revenue in the last twelve months to $116.93M, up 4.08% year-over-year. In the year 2025, ARS Pharmaceuticals had annual revenue of $84.28M, down -5.46%.
Revenue (ttm)
$116.93M
Revenue Growth
+4.08%
P/S Ratio
4.45
Revenue / Employee
$584,635
Employees
200
Market Cap
511.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 84.28M | -4.87M | -5.46% |
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 117.39M |
| Scribe Therapeutics | 33.30M |
| Prelude Therapeutics | 22.42M |
| Capricor Therapeutics | 11.13M |
| Ovid Therapeutics | 1.58M |
| Artiva Biotherapeutics | 251.00K |
| Entera Bio | 42.00K |
SPRY News
- 1 day ago - Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 2 days ago - ARS Pharmaceuticals price target lowered to $15 from $18 at Leerink - TheFly
- 8 days ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 13 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY - PRNewsWire
- 19 days ago - SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses - GlobeNewsWire
- 23 days ago - Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026 - Newsfile Corp
- 24 days ago - ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c) - TheFly